



Press Release

Media contact

Rhiannon Bugno

+1 254 522 9700

Biol.Psych@sobp.org

New insights into lithium's effectiveness for bipolar disorder

Study in Biological Psychiatry finds gene imparts neural proliferation sensitivity to lithium

Philadelphia, October 18, 2022 – Bipolar disorder, a neuropsychiatric condition that includes manic and depressive episodes, affects about 1% of the population and is strongly influenced by genetics. About half of patients respond very well to lithium salts as a therapy, and treatment responsiveness also depends on genetics. Researchers still have little idea of how lithium works to stabilize mood, but, similar to other anti-depressants, it stimulates proliferation of adult neural progenitor cells (NPC), perhaps leading to the birth of new neurons. Now, a [new study](#) identifies a specific gene that seems to regulate NPC proliferation in response to lithium.

The study, led by Jason Stein, PhD, at The University of North Carolina at Chapel Hill, appears in [Biological Psychiatry](#), published by Elsevier.

“Some people with bipolar disorder show therapeutic responses to lithium, while others do not,” said Dr. Stein. “Previous studies have identified a limited number of genetic variations contributing to lithium’s clinical outcomes. These studies are incredibly important, but are also costly, require large sample sizes, and do not identify cell types or biological processes mediating genetic effects. Here, we took an alternative approach by performing a genome-wide association study (GWAS) in a cell culture system from multiple human donors, either exposed to or not exposed to lithium.”

To measure lithium-induced neural proliferation, the researchers employed a cell culture of human NPCs obtained from fetal brain tissue. Some cultures were exposed to lithium, which increased cell proliferation, whereas other cultures were not. The authors then performed GWAS tests.

“Our cell-culture based GWAS approach identified genetic variation as well as a specific gene that influenced lithium-responsive neural progenitor proliferation,” said Dr. Stein.

John Krystal, MD, editor of *Biological Psychiatry*, said of the study, “The efficacy of lithium remains one of the great mysteries in psychiatry. Emerging from an accidental discovery, it remains a wonder drug for many patients. This study identifies mechanisms underlying the ability of lithium to stimulate proliferation of neural progenitor cells. In particular, they implicate chromosome 3p21.1 and the guanine nucleotide-binding protein-like 3 (GNL3) gene in this effect. GNL3 has been implicated previously in cell cycle regulation and cellular differentiation.”

GNL3 has also been implicated in risk for bipolar disorder, schizophrenia and inter-individual variations in intelligence, suggesting the gene plays an important role in brain function.

Using CRISPR technology, the researchers then increased expression of *GNL3* in the cultures, which in turn increased neural proliferation in response to lithium. Conversely, decreasing expression of *GNL3* decreased lithium-induced proliferation.

“Though more experiments are required to determine if these results have clinical potential, this study opens up a new approach of identifying pharmacogenomic effects in cell culture systems,” added Dr. Stein.

Notes for editors

The article is “Cellular genome-wide association study identifies common genetic variation influencing lithium induced neural progenitor proliferation,” by Justin M. Wolter, Brandon D. Le, Nana Matoba, Michael J. Lafferty, Nil Aygün, Dan Liang, Kenan Courtney, Juan Song, Joseph Piven, Mark J. Zylka, and Jason L. Stein (<https://doi.org/10.1016/j.biopsych.2022.08.014>). It appears as an Article in Press in *Biological Psychiatry*, published by Elsevier.

Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at +1 254 522 9700 or Biol.Psych@sobp.org. Journalists wishing to interview the authors may contact Jason L. Stein at jason_stein@med.unc.edu.

The authors' affiliations and disclosures of financial and conflicts of interests are available in the article.

John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available [here](#).

About *Biological Psychiatry*

Biological Psychiatry is the official journal of the [Society of Biological Psychiatry](#), whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.

The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.

Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 12th out of 155 Psychiatry titles and 14th out of 274 Neurosciences titles in the Journal Citations Reports™ published by Clarivate Analytics. The 2021 Impact Factor score for *Biological Psychiatry* is 12.810. www.sobp.org/journal

About Elsevier

As a global leader in information and analytics, [Elsevier](#) helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.

In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.

Elsevier employs 8,700 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as [ScienceDirect](#), [Scopus](#), [SciVal](#), [ClinicalKey](#) and [Sherpath](#) support strategic [research management](#), [R&D performance](#), [clinical decision support](#), and [health education](#). Researchers and healthcare professionals rely on our over 2,700 digitized journals, including *The Lancet* and *Cell*; our over 43,000 eBook titles; and our iconic reference works, such as *Gray's Anatomy*. With the [Elsevier Foundation](#) and our external [Inclusion & Diversity Advisory Board](#), we work in partnership with diverse stakeholders to advance [inclusion and diversity](#) in science, research and healthcare in developing countries and around the world.

Elsevier is part of [RELX](#), a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com

Media contact

Rhiannon Bugno, Editorial Office

Biological Psychiatry

+1 254 522 9700

Biol.Psych@sobp.org